Pioneer Institute Recommends Reforms Amid Rise In 340B Restrictions

The number of drug makers that restrict 340B discounts rose to 16 this month with announcements by Gilead and Johnson & Johnson, who plan to require that hospitals share claims data in return for discounts on drugs they buy through contract pharmacies. The drug makers say their goal is to avoid duplicate discounts, and the Pioneer Institute released a paper Tuesday (Mar. 22) with brand-friendly recommendations for reforming the 340B program, including suggestions for resolving the issues of duplicate drug...
Article Type: 
Site Name:
IDP Issue: 
Inside Drug Pricing - 03/28/2022
IDP Volume: 
Vol. 5, No. 13

FDA Shares Abbott Infant Formula Inspection Info Amid Lawmaker Scrutiny

FDA on Tuesday (March 22) released inspection reports dating back to 2019 detailing contamination control issues at one of Abbott Nutrition’s facilities that manufactured the infant formula recently recalled from the market due to reports of bacterial infection in infants who consumed the product. Key senators described the findings as “deeply troubling” and said it’s now even more urgent that Abbott and FDA provide answers on why the contamination occurred. FDA was already under scrutiny for how it handled the...
Article Type: 
Site Name:
FDA Issue: 
FDA Week - 04/01/2022
FDA Volume: 
Vol. 28, No. 13

Providers Demand Surge-Related Relief Separate From WH Request

Providers are ramping up their calls for Congress to allocate additional COVID-19 relief that HHS could use to directly reimburse providers for costs related to Delta and Omicron variant surges while the Biden administration pressures lawmakers into passing targeted relief would just replenish the uninsured program and fund various vaccine treatment projects. The Biden administration had asked Congress earlier in March for an additional $22.5 billion in COVID-19 relief , announcing that HHS had spent or allocated more than 90%...
Article Type: 
Site Name:
CMS Issue: 
Inside CMS - 03/31/2022
CMS Volume: 
Vol. 25, No. 13


Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.